Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system

A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:

• an active compound in an amount of between 0.1 and 25 percent by weight of the total composition selected from the group consisting of consisting of acetylcholinesterase inhibitors, nerve impulse inhibitors, anti-cholinergics, anti-convulsants, anti-psychotics, anxiolytic agents, dopamine metabolism inhibitors, agents to treat post stroke sequelae, neuroprotectants, agents to treat Alzheimer's disease, neurotransmitters, neurotransmitter agonists, sedatives, agents for treating attention deficit disorder, agents for treating narcolepsy, central adregenic antagonists, anti-depression agents, agents for treating Parkinson's disease, benzodiazepine antagonists, stimulants, neurotransmitter antagonists, tranquilizers, and mixtures thereof;
• a polar solvent in an amount between 10 and 97 percent by weight of the total composition;
• and
• a propellant in an amount between 2 and 10 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration.

A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:

• an active compound in an amount between 0.05 and 50 percent by weight of the total composition selected from the group consisting of acetylcholinesterase inhibitors, nerve impulse inhibitors, anti-cholinergics, anti-convulsants, anti-psychotics, anxiolytic agents, dopamine metabolism inhibitors, agents to treat post stroke sequelae, neuroprotectants, agents to treat Alzheimer's disease, neurotransmitters, neurotransmitter agonists, sedatives, agents for treating attention deficit disorder, agents for treating narcolepsy, central adregenic antagonists, anti-depression agents, agents for treating Parkinson's disease, benzodiazepine antagonists, stimulants, neurotransmitter antagonists, tranquilizers, and mixtures thereof;
• and
• a non-polar solvent in an amount between 19 and 85 percent by weight of the total composition;
• and
• a propellant in an amount between 5 and 80 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or brancehed configuration.

A buccal spray composition for transmucosal administration of a pharmacologically active compound comprising:

• an active compound in an amount between 0.01 and 40 percent by weight of the total composition selected from the group consisting of acetylcholinesterase inhibitors, nerve impulse inhibitors, anti-cholinergics, anti-convulsants, anti-psychotics, anxiolytic agents, dopamine metabolism inhibitors, agents to treat post stroke sequelae, neuroprotectants, agents to treat Alzheimer's disease, neurotransmitters, neurotransmitter agonists, sedatives, agents for treating attention deficit disorder, agents for treating narcolepsy, central adregenic antagonists, anti-depression agents, agents for treating Parkinson's disease, benzodiazepine antagonists, stimulants, neurotransmitter antagonists, tranquilizers, and mixtures thereof;
• and
• a non-polar solvent in an amount between 25 and 89 percent by weight of the total composition;
• a propellant in an amount between 10 and 70 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or brancehed configuration;
• and
• A flavoring agent is present in an amount between 1 and 8 percent by weight of the total composition.